NASDAQ$CUE

Cue Biopharma Inc · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Headline financials

Total Revenue

$2.74M

Previous: $1.08M+154.8%
EPS (adj)

-$0.33

Previous: -$0.38+13.2%
Capital Expenditures

-$900K

Previous: -$141K-538.3%
Free Cash Flow

-$11.2M

Previous: -$11M-1.9%
Net Income

-$10.3M

Previous: -$10.8M+5.1%
Operating Income

-$10.3M

Previous: -$10.9M+5.8%

Revenue & EPS history

Cue Biopharma · Revenue · Quarterly

$2.74M

Q2 2021+154.8%vs Q2 2020
Beat estimate in 2 of 5 quarters(40%)
ActualEstimate

Revenue by segment

Cue Biopharma · $5.69M total across 1 segment · Q1 2026

  • Collaboration revenue
    $5.69M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

-0.1%

Avg return

Earnings day

-1.2%

Avg return

5 days after

+1.3%

Avg return

30 days after

45%

15 / 33 earnings

Positive

+25.2%

Q4 2021

Best reaction

-16.7%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-14.2%-31.0%
Q4 2025-0.3%-14.7%+97.1%
Q3 2025-8.5%-13.2%-27.1%
Q2 2025+0.0%+3.7%-6.1%
Q1 2025-3.5%-2.5%-18.6%
Q4 2024+3.3%-2.4%-9.4%
Q3 2024-16.7%-28.0%-37.3%
Q2 2024-6.3%+19.9%-7.1%
Q1 2024-8.9%-18.8%-22.5%
Q4 2023+2.7%-5.4%+3.2%
Q3 2023+14.9%+5.4%+8.1%
Q2 2023-12.3%-14.2%-26.5%
Q1 2023-3.7%-12.4%-23.2%
Q4 2022+7.1%+7.4%+14.2%
Q3 2022+20.4%+2.5%-6.1%
Q2 2022+1.7%-5.7%+3.3%
Q1 2022-11.0%-10.0%-8.5%
Q4 2021+25.2%+27.2%+2.9%
Q3 2021-0.4%+6.4%+4.1%
Q2 2021+7.7%+3.5%+23.1%
Q1 2021-1.4%+2.4%-4.2%
Q4 2020-7.5%-4.5%-14.3%
Q3 2020+11.2%+7.1%+17.3%
Q2 2020+1.3%+2.5%-16.0%
Q1 2020+8.3%+13.3%-4.4%
Q4 2019-15.5%+4.8%+59.8%
Q3 2019-2.0%-1.8%+38.4%
Q2 2019+1.3%+7.5%+6.4%
Q1 2019+0.1%+1.5%-6.7%
Q4 2018+9.7%+23.8%+20.3%
Q3 2018-6.7%-8.8%-16.2%
Q2 2018-0.7%-4.9%+11.3%
Q4 2017+0.5%+1.2%-13.5%
Q2 2017
Q1 2017
Q4 2016
Q3 2016
Q2 2016
Q1 2016

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro